CID4 Is Focused On

Advancing the Colorado life science ecosystem through company creation and job growth. Active management, consulting services and capital work in tandem to bridge the gap between discovery and commercialization.

Our Passion Is

Assisting outstanding life science entrepreneurs and academicians; to help turn promising ideas and discoveries into market-defining and market-leading companies

.

CID4’s Team Are

Experienced life science technology leaders, entrepreneurs and investors. We know from first-hand experience the joys (and pains) of starting and growing life science companies.

Stay Current With CID4

Stay up to date on the
latest news from CID4.


CID4 Twitter Feed


Read The CID4 Report

The CID4 Report Vol. I No. I The CID4 Report Vol. I No. I (2765 KB)

View All

Blog Topics

NEW! Submit your business plan to be considered for CID4's next portfolio company - click here. Deadline March 24, 2014.

 

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to:

  • Advance the Colorado bioscience ecosystem through company creation and job growth.

Active business management and capital work in tandem to help bridge the gap between discovery and product development.

CID4 Diagram

Colorado has a long and successful history in the life sciences. A sampling of biotechnology companies have included: Synergen (acquired by Amgen), Somatagen (acquired by Baxter), NexStar (acquired by Gilead), Ribozyme/siRNA (acquired by Merck), Dharmacon (acquired by Thermo Fisher), Pharmion (acquired by Celgene), Insmed (acquired by Merck) and Taligen (acquired by Alexion); A sampling of medical device companies have included Cobe (Gambro), Valley Labs (Covidien) and CaridianBCT (Terumo); And numerous going concerns who have recently raised venture capital dollars include: Clovis Oncology, GlobeImmune, Allos Therapeutics, Array Pharmaceuticals, ARCA biopharma, SomaLogic, Miragen and Biodesix.

Access to early-stage venture capital has become increasingly difficult and the “Valley of Death” or the period between discovery and entering the clinic, continues to widen, in part, as a function of risk capital continuing to migrate away from the early-stage entity and instead towards larger and later-stage deals.

CID4 works to identify, fund and actively manage emerging life science technologies, this aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management and TBAC members.